Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Sponsor
Nanfang Hospital, Southern Medical University
Study ID
NCT05171309
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    250 mg once daily (QD) oral dosing.
  • Camrelizumab — DRUG
    200 mg intravenously every 2 weeks.
  • NK cell — DRUG
    Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days

Study Details

The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in combination with apatinib plus NK cell in patients with advanced hepatocellular carcinoma.

Key Dates

Start date
Jan 1, 2021
Status verified
Nov 2021
Primary completion
Dec 31, 2022
Completion
Dec 31, 2023

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab in combination with apatinib plus NK cell
    Drug: Apatinib 250 mg once daily (QD) oral dosing. Other Names: • Apatinib Drug: Camrelizumab 200 mg intravenously every 2 weeks. Other Names: • Camrelizumab Drug: NK cell Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years) ]

Central Contacts

Related Studies